Journal Article

Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects

Aragona, Caterina Oriana, Cairo, Valentina, Lo Gullo, Alberto, Loddo, Saverio, Mormina, Enricomaria, Saitta, Antonino, Basile, Giorgio, Scuruchi, Michele, Alibrandi, Angela, Mandraffino, Giuseppe, Imbalzano, Egidio, D’Ascola, Angela, Quartuccio, Sebastiano, Morace, Carmela

2017

Overview

CD34+ circulating progenitor cells (CD34+CPCs) are a population of multipotent cells which can delay the development of atherosclerosis and cardiovascular disease (CVD) in conditions of increased CV risk. MicroRNAs (miRs) 221 and 222 modulate different genes regulating angiogenesis and inflammation; moreover, miR221/22 have beenshown to participate in differentiation and proliferation of CD34+CPCs, inhibiting cell migration and homing. miR221/222 in CD34+CPCs from hypertensive subjects are also increased and associated with CD34+cell number and reactive oxygen species (ROS). We evaluated CD34+CPC number, intracellular miR221/222 and ROS levels, arterial stiffness (AS)and echocardiography indices at baseline (T0).Then, after a six-month treatment with olmesartan, 20 mg/day (T1), in 57 hypertensive patients with left ventricular hypertrophy (LVH) and with no additional risk factor for CVD, and in 29 healthy controls (baseline),fibrinogen, C-reactive protein (CRP), glucose and lipid profiles were also evaluated.At T1, blood pressure values, CRP and fibrinogen levels, ROS and miR221/222 were significantly decreased (all p <0.001), as were AS indices and LV mass index (p<0.001), while cell number was increased (p<0.001). Olmesartan is effective in reducing miR and ROS levels in CD34+CPCs from hypertensive subjects, as well as in increasing CD34+CPC number, providing multilevel CV protection, in addition to its expected pharmacological effects.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: Adult / Analysis / Angiogenesis / Antigens, CD34 - blood / Antihypertensive Agents - therapeutic use / Arteriosclerosis / Atherosclerosis / Biology and Life Sciences / Blood pressure / C-reactive protein / Cardiovascular diseases / CD34 antigen / CD4 lymphocytes / Cell differentiation / Cell migration / Cell number / Cell proliferation / Cells (biology) / Dosage and administration / Drug therapy / Echocardiography / Female / Fibrinogen / Gene expression / Heart / Homeostasis / Homing / Humans / Hypertension / Hypertension - blood / Hypertension - drug therapy / Hypertension - genetics / Hypertrophy / Imidazoles - therapeutic use / Male / Medicine / Medicine and Health Sciences / MicroRNAs / MicroRNAs - blood / Middle Aged / miRNA / Olmesartan medoxomil / Oxidative stress / Oxygen / Pharmacology / Physiology / Progenitor cells / Reactive oxygen species / Reactive Oxygen Species - metabolism / Risk factors / Rodents / Smooth muscle / Stem cells / Stem Cells - pathology / Stiffness / Tetrazoles - therapeutic use / Treatment outcome / Ventricle